BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF)'s Kenneth Kovan and Yvelise Barrios joined Proactive to discuss how its global CDMO partner WuXi Biologics has completed the synthesis of recombinant SARS-CoV-2 s-protein for the BVX-0320 and CoviDTH programs.
BVX-0320 is BioVaxys’ COVID-19 vaccine candidate and CoviDTH its immunodiagnostic product. Both are headed for clinical trials, with BioVaxys having begun preparing an Investigational New Drug submission to the US Food and Drug Administration for a combined Phase I/II clinical study of CoviDTH as a diagnostic for evaluating T-cell immune response to SARS-CoV-2.